» Articles » PMID: 35326457

Stabilization of PIM Kinases in Hypoxia Is Mediated by the Deubiquitinase USP28

Overview
Journal Cells
Publisher MDPI
Date 2022 Mar 25
PMID 35326457
Authors
Affiliations
Soon will be listed here.
Abstract

Proviral integration sites for Moloney murine leukemia virus (PIM) kinases are upregulated at the protein level in response to hypoxia and have multiple protumorigenic functions, promoting cell growth, survival, and angiogenesis. However, the mechanism responsible for the induction of PIM in hypoxia remains unknown. Here, we examined factors affecting PIM kinase stability in normoxia and hypoxia. We found that PIM kinases were upregulated in hypoxia at the protein level but not at the mRNA level, confirming that PIMs were upregulated in hypoxia in a hypoxia inducible factor 1-independent manner. PIM kinases were less ubiquitinated in hypoxia than in normoxia, indicating that hypoxia reduced their proteasomal degradation. We identified the deubiquitinase ubiquitin-specific protease 28 (USP28) as a key regulator of PIM1 and PIM2 stability. The overexpression of USP28 increased PIM protein stability and total levels in both normoxia and hypoxia, and USP28-knockdown significantly increased the ubiquitination of PIM1 and PIM2. Interestingly, coimmunoprecipitation assays showed an increased interaction between PIM1/2 and USP28 in response to hypoxia, which correlated with reduced ubiquitination and increased protein stability. In a xenograft model, USP28-knockdown tumors grew more slowly than control tumors and showed significantly lower levels of PIM1 in vivo. In conclusion, USP28 blocked the ubiquitination and increased the stability of PIM1/2, particularly in hypoxia. These data provide the first insight into proteins responsible for controlling PIM protein degradation and identify USP28 as an important upstream regulator of this hypoxia-induced, protumorigenic signaling pathway.

Citing Articles

PIM1 signaling in immunoinflammatory diseases: an emerging therapeutic target.

Yang X, Liu C, Lei Y, Liu Z, Zhu B, Zhao D Front Immunol. 2024; 15:1443784.

PMID: 39372407 PMC: 11449710. DOI: 10.3389/fimmu.2024.1443784.


Cinobufotalin regulates the USP36/c-Myc axis to suppress malignant phenotypes of colon cancer cells and .

Hu Y, Luo M Aging (Albany NY). 2024; 16(6):5526-5544.

PMID: 38517383 PMC: 11006458. DOI: 10.18632/aging.205661.


PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer.

Torres-Ayuso P, Katerji M, Mehlich D, Lookingbill S, Sabbasani V, Liou H Cell Chem Biol. 2023; 31(2):326-337.e11.

PMID: 38016478 PMC: 10922308. DOI: 10.1016/j.chembiol.2023.10.023.


Pim Kinases: Important Regulators of Cardiovascular Disease.

Nock S, Karim E, Unsworth A Int J Mol Sci. 2023; 24(14).

PMID: 37511341 PMC: 10380471. DOI: 10.3390/ijms241411582.


PIM1 phosphorylates ABI2 to enhance actin dynamics and promote tumor invasion.

Jensen C, Clements A, Liou H, Ball L, Bethard J, Langlais P J Cell Biol. 2023; 222(6).

PMID: 37042842 PMC: 10103708. DOI: 10.1083/jcb.202208136.


References
1.
Komatsu D, Hadjiargyrou M . Activation of the transcription factor HIF-1 and its target genes, VEGF, HO-1, iNOS, during fracture repair. Bone. 2004; 34(4):680-8. DOI: 10.1016/j.bone.2003.12.024. View

2.
Du S, Zhu L, Wang Y, Liu J, Zhang D, Chen Y . SENP1-mediated deSUMOylation of USP28 regulated HIF-1α accumulation and activation during hypoxia response. Cancer Cell Int. 2019; 19:4. PMC: 6317191. DOI: 10.1186/s12935-018-0722-9. View

3.
Nawijn M, Alendar A, Berns A . For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer. 2010; 11(1):23-34. DOI: 10.1038/nrc2986. View

4.
Welcker M, Clurman B . FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2007; 8(2):83-93. DOI: 10.1038/nrc2290. View

5.
Chen J, Kobayashi M, Darmanin S, Qiao Y, Gully C, Zhao R . Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene. 2009; 28(28):2581-92. PMC: 3358117. DOI: 10.1038/onc.2009.124. View